Q-omics provides the consensus-scored E2F2 profile across patient tissues and cancer cell-line models. E2F2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, E2F2 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, E2F2 RNA expression shows 25,689 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where E2F2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for E2F2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes E2F2 survival associations across molecular data types. E2F2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible E2F2 RNA expression–survival associations across cancer types. High E2F2 expression shows unfavorable associations in ACC, KIRP, KICH, LIHC and KIRC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for E2F2 RNA expression.
This table summarizes E2F2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for E2F2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. E2F2 shows higher tumor expression in BLCA, KIRP, KIRC, LUAD, LIHC and UCEC. The BLCA box plot shows higher E2F2 RNA expression in tumor versus normal tissue (log2 FC = +2.024, t-test p < 0.001).
This table shows molecular features associated with E2F2 in patient tissues and cancer cell lines. In patient samples, E2F2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, E2F2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
